Place · Level 3 · Supplement
Lutein + Zeaxanthin · Macular Pigment
AREDS2 NEJM 黄斑变性 A 级 · 10 + 2 mg/天 · 蓝光营销大量虚假 · 整食物 (深绿叶、蛋黄) 优先
Last updated
Story path
Chapter 1
Macular pigment
Macular pigment
Lutein and zeaxanthin are the only two members of the carotenoid family that accumulate in the retinal macula at 1000× plasma concentrations.
Chemistry:
Carotenoids (same family as β-carotene + lycopene)Yellow / orange pigmentsPlant-derived — humans cannot synthesise them, dietary intake required
Body distribution:
Retinal macula: extremely concentrated — forms the "macular pigment (MP)"Cornea / lens: lowerBrain + skin: traceMacular pigment optical density (MPOD) can be clinically measured — inversely associated with AMD risk
Function (dual):
① Blue-light filtering: MP selectively absorbs 400-500 nm blue light → reduces retinal photo-oxidative damage
② Antioxidant: the retina has one of the body's highest metabolic rates + continuous light exposure + high PUFA membranes = extremely susceptible to oxidative damage. Lutein/Zea are the front-line antioxidants
Why this island is required on the atlas:
AREDS2 2013 JAMA — the second-most-famous nutritional RCT (after WHI); Level A evidence for AMDAge-related macular degeneration (AMD) is the leading cause of blindness in 65+ y/oChinese 65+ AMD prevalence ~ 10%, US ~ 15%"Blue-light glasses / anti-blue-light supplements" are heavily marketed; the atlas debunks themWhole foods (dark leafy greens + egg yolks) beat supplements — but supplements have value in specific populations
Chemistry:
Carotenoids (same family as β-carotene + lycopene)Yellow / orange pigmentsPlant-derived — humans cannot synthesise them, dietary intake required
Body distribution:
Retinal macula: extremely concentrated — forms the "macular pigment (MP)"Cornea / lens: lowerBrain + skin: traceMacular pigment optical density (MPOD) can be clinically measured — inversely associated with AMD risk
Function (dual):
① Blue-light filtering: MP selectively absorbs 400-500 nm blue light → reduces retinal photo-oxidative damage
② Antioxidant: the retina has one of the body's highest metabolic rates + continuous light exposure + high PUFA membranes = extremely susceptible to oxidative damage. Lutein/Zea are the front-line antioxidants
Why this island is required on the atlas:
AREDS2 2013 JAMA — the second-most-famous nutritional RCT (after WHI); Level A evidence for AMDAge-related macular degeneration (AMD) is the leading cause of blindness in 65+ y/oChinese 65+ AMD prevalence ~ 10%, US ~ 15%"Blue-light glasses / anti-blue-light supplements" are heavily marketed; the atlas debunks themWhole foods (dark leafy greens + egg yolks) beat supplements — but supplements have value in specific populations
机制 · 为什么伤害落在黄斑
黄斑不是随便哪块组织。它是光线被晶状体聚焦以后正好落下来的那个点, 也是视网膜上感光细胞挤得最密的地方。要看懂那两个色素在防什么, 得先看清这一小块地方每天在承受什么。第一步 · 这里的膜天生就怕氧化。 感光细胞的顶端是一叠层层码起来的膜盘, 光子就是在这些膜上被抓住的。这些膜里塞满了多不饱和脂肪 (PUFA)——分子链上带很多双键, 因此柔软、流动性好, 感光蛋白必须泡在这样的膜里才转得动。但双键正是氧最爱下手的位置。让膜好用的那个性质, 同时让它易燃。
第二步 · 最强的光和最高的耗氧, 压在同一小块上。 感光细胞每接一次光信号都要大量耗氧, 而它们又是全身唯一被要求整天对着光看的细胞。高耗氧意味着代谢过程中不断有活性氧漏出来, 强光意味着蓝光那一端的光子能量足以直接把一个分子打成自由基。易燃的材料、火星、助燃的氧, 三样凑齐在同一小块组织里。
第三步 · 被氧化的膜, 变成必须天天清走的垃圾。 膜盘上的脂肪一旦被氧化就废了。感光细胞的对策很暴力: 每天把最外层的旧膜盘整批扔掉, 由紧贴在它下面的一层视网膜色素上皮 (RPE) 吞掉、拆解、把还能用的原料还回去。这是全身最繁重的清洁流水线之一, 一刻不停地干几十年。
第四步 · 清洁工老了, 垃圾开始堆。 氧化过的脂肪碎片特别难拆。年复一年, RPE 细胞里消化不掉的残渣越积越多, 它自己的处理能力跟着下降, 来不及运走的东西开始堆在 RPE 底下——那就是眼底检查报告上写的黄白色沉积。这层堆积物卡在感光细胞和它下面供氧的血管层之间, 等于给全身最耗氧的细胞加了一道墙。
第五步 · 中央先失守。 拿不到足够补给、又清不掉自己废物的感光细胞, 会一片片死掉。死在视网膜边缘, 你可能一辈子察觉不到; 死在黄斑正中央, 丢掉的正是看清字、认清脸的那块视野——四周还看得见, 中间糊成一团。这就是老年黄斑变性走到最后的样子, 也是它成为 65 岁以上致盲首要原因的原因。
叶黄素和玉米黄质只在这条链的前两步上干活。 它们不修 RPE, 也救不回已经死掉的细胞, 只做两件事: 在光打到膜盘之前把最高能的那段蓝光吸掉 (少一点火星), 以及在膜里当那个先被氧化的分子、替脂肪挡一下 (少一点起火)。所以它们能做到的是把这条链拖慢, 不是把它倒回去——这也正是为什么 AREDS2 (2013 JAMA) 量出来的结果是进展变慢, 而不是视力变好。
化学与分布 · 它们从哪来
化学:类胡萝卜素 (与 β-胡萝卜素、番茄红素同家族)黄色、橙色色素来自植物——人不能自合成, 必须膳食
身体分布:
视网膜黄斑: 浓度极高, 形成黄斑色素 (macular pigment, MP)角膜、晶状体: 较低大脑、皮肤: 微量MP 密度 (MPOD) 可临床测量, 与黄斑变性风险呈反向关联
功能 (双重):
滤蓝光: MP 选择性吸收 400–500 nm 蓝光, 减少视网膜光氧化损伤抗氧化: 视网膜是全身代谢率最高组织之一, 持续光照与高 PUFA 膜让它极易氧化损伤; Lutein/Zea 是抗氧化前线
为什么偏偏是这两个进得去。 类胡萝卜素这一家成员众多, 血里同时流着好几种, 但黄斑里只找得到叶黄素和玉米黄质。差别在分子的两头: 这两个分子的末端各带一个羟基, 属于类胡萝卜素里含氧的那一支; β-胡萝卜素、番茄红素则是纯碳氢的一支。多出来的羟基让分子两头略微亲水, 于是它能横着插进细胞膜、两头露在水里站稳, 像一根钉在膜上的横梁; 纯碳氢的成员摆不出这个姿势, 只能瘫在膜的油相里随波逐流。能不能在膜上站稳, 是黄斑挑人的第一道门槛。
而血浆浓度的巨大落差, 说明还有第二道门。 浓度差不会自己长出来: 光靠扩散, 组织里的浓度最多和血里持平。要在黄斑里堆出血浆 1000 倍的量, 必须有东西主动把它们拽进去、并且扣住不放。这就是为什么吃再多 β-胡萝卜素也补不出黄斑色素——它连第一道门都过不去, 更谈不上被专车送进去。
MPOD 是这条长链上唯一量得到的中间指标。 黄斑色素的厚度可以在部分眼科诊所直接测出来。它的价值在于: 从吃进嘴里到黄斑变性进展变慢, 中间隔着几十年, 没有人等得起; 而 MPOD 上升至少说明色素真的堆进去了。反过来也成立——一款补剂如果连 MPOD 都推不动, 后面的事根本不用谈。
推演 · 你自己能推出什么
机制的价值在于能省掉背诵。 上面那条链一旦跑通, 下面几个常被问到的问题, 你自己就能推出答案。为什么补剂不可能让视力立刻变清楚? 因为它改的是色素的厚度, 而色素要靠血液一点点运进黄斑、慢慢堆起来。厚度上去以后, 它挡住的也只是往后的光氧化; 已经被氧化的膜、已经堆在 RPE 底下的沉积、已经死掉的感光细胞, 一个都追不回来。所以它的效果只可能表现为进展变慢, 而进展本身是以年计的。一款说自己吃两周就让视力变好的护眼产品, 不用查成分就知道它在讲什么。
为什么强日光比屏幕重要得多? 因为这条链的第一步是能量。同一段蓝光波长, 能不能把分子打成自由基, 取决于单位时间打进来多少光子。日光和屏幕之间差着几百倍, 滤镜真正要防的显然是前者。这也是为什么高原、水面、雪地、常年户外作业会被算进风险, 而每天盯屏幕不算。
为什么吸烟排在可控风险的第一位? 因为它从这条链的另一端进攻: 烟雾本身就是一大股氧化剂, 等于在同一块组织上额外点了一把火, 而黄斑的清洁流水线原本就在满负荷运转。这也让护眼配方绕不开一个尴尬——上一代配方里的 β-胡萝卜素恰恰对吸烟者不安全, 而吸烟者又是最需要护眼配方的那群人。下一幕的试验就是为了解开这个死结。
为什么中央糊了、外围却还在? 因为色素浓度、光照强度、耗氧量, 这三样的峰值都挤在黄斑那一小块。视网膜别的地方同样在被氧化, 只是压力低得多, 也没人要求它分辨字形, 所以撑得住。走路没问题、看脸不行, 这个奇怪的组合正是从解剖上的这一小块推出来的。
那什么时候不该再自己推, 该去看医生? 视野正中央出现一小片空白或灰影、直线看起来变弯 (门框、瓷砖缝、稿纸的横线)、看东西中间发暗——这些不是用眼疲劳, 是黄斑本身在报警。出现这类变化请尽快去眼科检查, 不要先去买补剂。
Chapter 2
AREDS2 · AMD A-tier
AREDS2 · AMD A-tier
AREDS2 (Age-Related Eye Disease Study 2, 2013 JAMA):
Background:
AREDS1 (2001): antioxidants (vit C 500 mg + E 400 IU + Zn 80 mg + Cu 2 mg + β-carotene 15 mg) → AMD progression ↓ 25%Problem: β-carotene increases lung-cancer risk in smokers (ATBC + CARET); AREDS1 formula cannot be given to smokersAREDS2 goal: replace β-carotene + add lutein/zea + add omega-3, see if it improves
Design:
N = 4,203 early / intermediate AMD patientsMulti-arm RCT × 5 years:AREDS1 formula (with β-carotene)AREDS2 (lutein 10 mg + zea 2 mg, no β-carotene)+ omega-3 (DHA + EPA)Various combinations
Results:
Replacing β-carotene with lutein/zea: further reduces AMD progression, better safety (no β-carotene → smokers can also use it)Adding omega-3 (DHA + EPA): no significant benefit (another negative omega-3 RCT)New formula (AREDS2): vit C + E + Zn + Cu + lutein 10 mg + zea 2 mg5-year follow-up: AREDS2 vs AREDS1 AMD progression risk similar or better + improved safetySmokers: must use AREDS2 (no β-carotene)
Clinical translation:
Modern ophthalmology: intermediate-AMD patients are standardly recommended the AREDS2 formulaEarly AMD / AMD family history: discuss with ophthalmologyHealthy people without AMD: weak evidence; adequate dietary intake sufficesCataract: weak signal, not a primary indication
Hammond 2017 (healthy adults):
Lutein/zeaxanthin raised MPOD, with mild gains on visual and cognitive measuresParticipants did not have AMD — this is a wellness signal⚠️ This bullet used to be labelled the CARMA trial. CARMA is a different study (Beatty / Chakravarthy) that enrolled people with AMD, had no omega-3 arm, and reported in 2013 — two papers had been welded into one, with the population inverted. Old text: mild improvement in contrast sensitivity + glare recoveryNot AMD patients — a wellness signal
Bone 2007:
10 supplemented + 9 placebo, 120 days, 20 mg/day of a meso-zeaxanthin-dominant supplementIts only outcome is the rate of rise of macular pigment optical density⚠️ It measured no reading speed and no visual processing. This bullet used to read '12 mg lutein/day × 6 months' with those endpoints, and to co-cite a 'Stringham 2012' that does not exist
Background:
AREDS1 (2001): antioxidants (vit C 500 mg + E 400 IU + Zn 80 mg + Cu 2 mg + β-carotene 15 mg) → AMD progression ↓ 25%Problem: β-carotene increases lung-cancer risk in smokers (ATBC + CARET); AREDS1 formula cannot be given to smokersAREDS2 goal: replace β-carotene + add lutein/zea + add omega-3, see if it improves
Design:
N = 4,203 early / intermediate AMD patientsMulti-arm RCT × 5 years:AREDS1 formula (with β-carotene)AREDS2 (lutein 10 mg + zea 2 mg, no β-carotene)+ omega-3 (DHA + EPA)Various combinations
Results:
Replacing β-carotene with lutein/zea: further reduces AMD progression, better safety (no β-carotene → smokers can also use it)Adding omega-3 (DHA + EPA): no significant benefit (another negative omega-3 RCT)New formula (AREDS2): vit C + E + Zn + Cu + lutein 10 mg + zea 2 mg5-year follow-up: AREDS2 vs AREDS1 AMD progression risk similar or better + improved safetySmokers: must use AREDS2 (no β-carotene)
Clinical translation:
Modern ophthalmology: intermediate-AMD patients are standardly recommended the AREDS2 formulaEarly AMD / AMD family history: discuss with ophthalmologyHealthy people without AMD: weak evidence; adequate dietary intake sufficesCataract: weak signal, not a primary indication
Hammond 2017 (healthy adults):
Lutein/zeaxanthin raised MPOD, with mild gains on visual and cognitive measuresParticipants did not have AMD — this is a wellness signal⚠️ This bullet used to be labelled the CARMA trial. CARMA is a different study (Beatty / Chakravarthy) that enrolled people with AMD, had no omega-3 arm, and reported in 2013 — two papers had been welded into one, with the population inverted. Old text: mild improvement in contrast sensitivity + glare recoveryNot AMD patients — a wellness signal
Bone 2007:
10 supplemented + 9 placebo, 120 days, 20 mg/day of a meso-zeaxanthin-dominant supplementIts only outcome is the rate of rise of macular pigment optical density⚠️ It measured no reading speed and no visual processing. This bullet used to read '12 mg lutein/day × 6 months' with those endpoints, and to co-cite a 'Stringham 2012' that does not exist
试验设计 · 一个死结
(下面的 AMD 都指老年黄斑变性。)AREDS2 (Age-Related Eye Disease Study 2, 2013 JAMA)
背景:
AREDS1 (2001): 抗氧化 (Vit C 500 mg + E 400 IU + Zn 80 mg + Cu 2 mg + β-胡萝卜素 15 mg) 让 AMD 进展减少 25%问题: β-胡萝卜素让吸烟者肺癌风险上升 (ATBC + CARET 试验), AREDS1 公式不能给吸烟者AREDS2 目标: 替换 β-胡萝卜素, 加 Lutein/Zea, 加 omega-3, 看是否更好
设计:
N = 4,203 早、中期 AMD 患者多臂 RCT × 5 年:AREDS1 公式 (含 β-胡萝卜素)AREDS2 (Lutein 10 mg + Zea 2 mg, 无 β-胡萝卜素)加 omega-3 (DHA + EPA)各种组合
结果:
用 Lutein/Zea 替换 β-胡萝卜素: AMD 进展进一步下降, 安全性更优 (不含 β-胡萝卜素, 吸烟者也能用)加 omega-3 (DHA + EPA): 无显著效益 (omega-3 RCT 又一次阴性)新公式 (AREDS2): Vit C + E + Zn + Cu + Lutein 10 mg + Zea 2 mg5 年随访: AREDS2 vs AREDS1 AMD 进展风险相似或更优, 安全性更好吸烟者: 必须用 AREDS2 (不含 β-胡萝卜素)
多臂设计是这个试验最值钱的地方。 它不是拿一个新配方跟安慰剂比, 而是把换成分和加成分两件事分开问: 一组换掉那味有安全问题的, 一组在原配方上加鱼油, 还有各种组合。所以它同时给出了两个方向的答案——换是安全的, 加是没用的。如果只做一个整体配方对安慰剂, 你会知道配方管用, 却永远不知道是里面哪一味在管用、哪一味只是搭车。
机制 · 换掉它为什么不是降级
试验只告诉你换了之后没有更差。为什么不会更差, 得回到上一幕那条链。β-胡萝卜素在这个配方里, 从来没在黄斑里干过活。 它属于类胡萝卜素里纯碳氢的一支, 进不了黄斑那道门——你吃再多, 黄斑色素也不会变厚。它在原配方里的角色是全身层面的抗氧化剂, 和维生素 C、维生素 E 一样, 泡在血里和组织里对付氧化。换句话说, 原配方对付黄斑的手段是远程的: 压低全身的氧化压力, 指望其中一部分惠及视网膜。
换上去的这两个, 是直接派到现场的。 叶黄素和玉米黄质会被搬进黄斑、插进感光细胞外面的膜、在光打到膜盘之前先把蓝光吸掉。同样一份剂量, 一个在全身兜圈子, 一个蹲在起火点上。所以这不是拿次品换正品, 是把一个远程的抗氧化剂, 换成一个能到岗的。
这条链顺带解释了鱼油为什么没测出效果。 鱼油里的 DHA 和 EPA 本身就是多不饱和脂肪——它们属于这条链里被氧化的那类分子, 不是防氧化的那类。感光细胞的膜盘之所以怕氧化, 正是因为里面这类脂肪多。往一块怕烧的材料里再添同类材料, 本来就缺一个让它更耐烧的理由。这不是说鱼油没用 (它在别处有别的作用), 而是说在黄斑这条特定的链上, 它站错了位置。
这一幕真正该带走的不是结论, 是提问的方式。 下次看到一个抗氧化护眼配方, 先问一句: 里面这味成分, 进得了黄斑吗? 进不去的, 它的作用就只能停在全身层面, 别指望它变成黄斑色素。
临床 · 谁该吃, 谁不必吃
临床转化:现代眼科: 中期 AMD 患者标准推荐 AREDS2 公式早期 AMD、有 AMD 家族史: 与眼科医生协商无 AMD 的健康人: 证据弱, 营养摄入足够即可白内障: 弱信号, 不是主适应症
Hammond 2017 (健康成人):
补 Lutein/Zea 后 MPOD 上升, 视觉与认知指标轻度改善受试者不是 AMD 患者, 属保健信号⚠️ 站内此前把这一条标成CARMA 试验, 那是另一回事: CARMA 是 Beatty / Chakravarthy 的试验, 入组的正是 AMD 患者, 没有 omega-3 组, 结果发表在 2013 年 —— 两篇被焊成了一条, 而且人群正好相反
Bone 2007:
10 人补剂 + 9 人安慰剂, 120 天, 每天 20 mg 以内消旋玉米黄质为主的配方它唯一的终点是黄斑色素光密度 (MPOD) 的上升速率⚠️ 它没有测阅读速度, 也没有测视觉处理。站内此前写的12 mg 叶黄素 × 6 个月以及那两个终点都不是这项研究的, 同时并列的Stringham 2012查无此文
这三条为什么要放在一起看。 中期患者那条是硬终点——眼睛有没有恶化到看不清; 健康人那两条是中间指标——色素厚了、对比敏感度好了一点。中间指标动了, 不等于将来真的少一个人失明: 这中间隔着几十年, 和一堆没人做过的试验。所以同一种营养素, 在两群人身上给出的建议强度天差地别——已经有病变的人, 配方是标准推荐; 没有病变的人, 证据只支持把菜吃够。
这也是读任何营养试验时最省事的一个动作: 先看它量的是什么。 量的是你最终怕的那件事 (失明、骨折、心梗), 结论就重; 量的是一个中间指标 (某个密度、某个血值), 结论就只能当线索。两者在广告里长得一模一样, 在证据等级上差着一整层。
Chapter 3
Food vs supplement
Food vs supplement
Whole-food Lutein/Zea content (mg/serving):
Kale (1 cup cooked): 25 mg — the championSpinach (1 cup cooked): 20 mgCollard greens / mustard greens / turnip greens: 10-15 mgBroccoli (1 cup cooked): 2-3 mgPeas / corn: 2-3 mgEgg yolk (1): 0.3-0.5 mg + a lipid carrier; bioavailability is very highCucumber / zucchini: 1-2 mgOranges / papaya / mango: 0.2-0.5 mg
Typical intake:
US NHANES: median 1-2 mg/day (most people well below recommendation)China (more vegetables + more eggs): average 2-3 mg/dayAREDS2 dose of 10 + 2 mg: requires 1 large cooked bowl of kale or spinach + an egg
Bioavailability:
Lutein from egg yolk: highest bioavailability — yolk lipids + phospholipids are natural carriers (Chung 2004)Cooked greens + oil (spinach sautéed with olive oil + garlic): good absorptionRaw greens (salad): moderateSupplement + fatty meal: goodSupplement + fasting: poor
Debunking "blue-light glasses + anti-blue-light supplements":
"Screen blue light causes macular damage / AMD": no RCT evidenceScreen blue-light intensity is far below natural sunlight"Anti-blue-light glasses": some evidence for reducing eye strain, but no evidence for preventing AMDReal AMD risk factors: smoking / genetics / UV / high-intensity blue light (sun, not screens) / poor nutrition + ageing"Anti-blue-light miracle formulas": mostly marketing — don't pay a premium for "screen protection"
"Dry eye / eye strain":
Lutein/Zea is not first-line for dry-eye syndrome (which is omega-3 / tear film / ambient humidity)Eye strain: brief eye exam / screen distance / 20-20-20 rule (every 20 minutes look 20 feet away for 20 seconds) outperforms supplements
Practice:
Healthy person: 1 cup of cooked greens + 1-2 eggs/day = 5-15 mg Lutein/Zea, sufficientEarly AMD / AMD family history / long-term sunlight exposure / older adults: consider AREDS2 formula (10 + 2 mg) — discuss with ophthalmologyDon't pay a premium for "anti-blue-light" marketing
Kale (1 cup cooked): 25 mg — the championSpinach (1 cup cooked): 20 mgCollard greens / mustard greens / turnip greens: 10-15 mgBroccoli (1 cup cooked): 2-3 mgPeas / corn: 2-3 mgEgg yolk (1): 0.3-0.5 mg + a lipid carrier; bioavailability is very highCucumber / zucchini: 1-2 mgOranges / papaya / mango: 0.2-0.5 mg
Typical intake:
US NHANES: median 1-2 mg/day (most people well below recommendation)China (more vegetables + more eggs): average 2-3 mg/dayAREDS2 dose of 10 + 2 mg: requires 1 large cooked bowl of kale or spinach + an egg
Bioavailability:
Lutein from egg yolk: highest bioavailability — yolk lipids + phospholipids are natural carriers (Chung 2004)Cooked greens + oil (spinach sautéed with olive oil + garlic): good absorptionRaw greens (salad): moderateSupplement + fatty meal: goodSupplement + fasting: poor
Debunking "blue-light glasses + anti-blue-light supplements":
"Screen blue light causes macular damage / AMD": no RCT evidenceScreen blue-light intensity is far below natural sunlight"Anti-blue-light glasses": some evidence for reducing eye strain, but no evidence for preventing AMDReal AMD risk factors: smoking / genetics / UV / high-intensity blue light (sun, not screens) / poor nutrition + ageing"Anti-blue-light miracle formulas": mostly marketing — don't pay a premium for "screen protection"
"Dry eye / eye strain":
Lutein/Zea is not first-line for dry-eye syndrome (which is omega-3 / tear film / ambient humidity)Eye strain: brief eye exam / screen distance / 20-20-20 rule (every 20 minutes look 20 feet away for 20 seconds) outperforms supplements
Practice:
Healthy person: 1 cup of cooked greens + 1-2 eggs/day = 5-15 mg Lutein/Zea, sufficientEarly AMD / AMD family history / long-term sunlight exposure / older adults: consider AREDS2 formula (10 + 2 mg) — discuss with ophthalmologyDon't pay a premium for "anti-blue-light" marketing
食物含量与吸收 · 数字都在这里
整食物 Lutein/Zea 含量 (mg/份):羽衣甘蓝 (Kale, 1 杯熟): 25 mg, 冠军菠菜 (1 杯熟): 20 mg甘蓝、芥菜、萝卜叶: 10–15 mg西兰花 (1 杯熟): 2–3 mg豌豆、玉米: 2–3 mg蛋黄 (1 个): 0.3–0.5 mg, 自带脂质载体, 生物利用度极高黄瓜、西葫芦: 1–2 mg橙子、木瓜、芒果: 0.2–0.5 mg
典型摄入:
美国 NHANES: 中位 1–2 mg/天 (大部分人远低于推荐)中国 (蔬菜吃得多、蛋也吃得多): 平均 2–3 mg/天AREDS2 剂量 10 + 2 mg: 需要 1 大碗熟羽衣甘蓝或菠菜, 再加 1 个蛋
生物利用度:
蛋黄中 Lutein 生物利用度最高: 蛋黄脂质与其中的磷脂是天然载体 (Chung 2004)熟绿叶配油 (橄榄油蒜炒菠菜): 良好吸收生绿叶 (沙拉): 中等补剂随含脂餐: 良好补剂空腹: 差
为什么加热和切碎这么关键。 叶黄素在绿叶菜里不是自由漂着的, 它被装在叶绿体的膜上, 而叶绿体外面还包着一层纤维素做的植物细胞壁——人的消化酶拆不动纤维素。细胞壁不破, 里面的东西就跟着粪便原样出去。加热让细胞壁软化破裂, 切碎和咀嚼从物理上把它撕开, 油则负责把释放出来的叶黄素接走: 它在肠道里必须先溶进油滴, 再被打包成一颗叫乳糜微粒的运输小球, 才有资格离开肠道进入淋巴、汇进血液。
这条链上少任何一步, 前面的步骤都白做。 一盘不放油的水煮菠菜和一盘蒜香油炒菠菜, 端上桌时含量一模一样, 进到血里的量却差得很远——差别不在菜, 在有没有把它接走的车。这也是为什么食物表上的数字只能当参考: 它标的是盘子里有多少, 不是你身体拿到多少。
误区 · 抗蓝光、干眼、护眼软糖
蓝光眼镜与抗蓝光补剂逐条比对:屏幕蓝光致黄斑损伤、致 AMD: 没有 RCT 证据屏幕蓝光强度远低于自然日光抗蓝光眼镜: 减少视疲劳有些证据, 但预防 AMD 无证据真正的 AMD 风险: 吸烟、遗传、紫外线、高强度蓝光 (日光, 不是屏幕)、营养差与衰老抗蓝光神奇配方: 大多是营销, 不要为屏幕保护付溢价
眼睛干、视疲劳:
Lutein/Zea 不是干眼症一线 (一线是 omega-3、泪膜、环境湿度)视疲劳: 短时眼镜验光、屏幕距离、20-20-20 规则 (20 分钟看 20 英尺远 20 秒) 比补剂效果好
实操:
健康人: 每天 1 杯熟绿叶菜配 1–2 个蛋 ≈ 5–15 mg Lutein/Zea, 足够早期 AMD、有 AMD 家族史、长期日光暴露、老年: 考虑 AREDS2 公式 (10 + 2 mg), 与眼科医生协商不要因抗蓝光营销付溢价
为什么这两件事总被混成一件。 眼睛累和黄斑受损, 在体验上完全不像。前者是用完就有、休息就好: 干、酸、聚焦变慢, 睡一觉基本复原; 后者是几十年不吭声, 一旦露面就不可逆: 中央视野的一小块糊掉, 休息不会让它回来。
营销把两者捆在一起卖, 靠的正是你分不清: 你每天真实感受到的是前者, 而你真正害怕的是后者, 于是一个能缓解前者的东西就被默认为在保护后者。但能缓解前者的手段 (休息、眨眼、验光、调屏幕距离) 一分钱不用花; 能影响后者的手段 (把色素堆厚) 你今天什么都感觉不到。 一个立刻让你觉得舒服的护眼产品, 恰恰证明它动的是前者。这两件事各归各, 不要用一份钱同时买单。
Chapter 4
Decision tree
Decision tree
Lutein/Zeaxanthin decision pathway:
Q1: What is your situation?
Healthy adult with greens / eggs in diet: food is sufficient, no supplement neededEarly / intermediate AMD: AREDS2 formula (vit C + E + Zn + Cu + lutein 10 + zea 2 mg) — under ophthalmologist guidanceAMD family history + 50+ y/o: consider prophylactic supplementation, discuss with ophthalmologyLong-term sun exposure + blue / light eyes: high AMD risk, sameCataract: no strong evidence, but supplementation acceptable
Q2: Choosing the form:
AREDS2 combination (full formula): major brands (PreserVision AREDS2, etc.) — standardSingle-ingredient lutein/zea: cheaper, but lacks the vit C + E + Zn + Cu synergyNatural source (marigold): dominant lutein source
Q3: Dose:
AREDS2 standard: 10 mg lutein + 2 mg zea/dayHigher doses (20 + 4 mg): some signal but weak evidenceMPOD testing: available at some ophthalmology clinics, assesses individual need
Q4: Take with fat:
Carotenoids must be co-ingested with fat for absorptionTake with a meal containing fatFasting absorption < 5%
Time to effect:
MPOD changes: 2-6 monthsAMD progression slowing: 1-3 years (chronic disease)"Instant sharper vision": wrong expectation — supplements do not immediately improve vision
Safety:
Very safe — food doses are extremely high (yellow skin from carotenes is pigment accumulation, not toxicity)AREDS2 dose: 5-year long-term safety data goodVery high doses (40+ mg/day): rare GI side effects
Don't buy:
"Anti-blue-light eye-care" combinations: overloaded formula + not on-target + marketing premium"Anti-myopia / lower diopter": no supplement reduces myopia (myopia is axial elongation, not pigment)"Children's eye-care gummies": mostly sugar + flavouring, low lutein content, real food is better
Connections to other atlas stories:
vitamin-a/vision L4 (complete visual chemistry)integumentary/uv-photoaging L4 (UV damage)fats-omega-3 + fish-oil (omega-3 was ineffective in AMD, review)multi-vitamin (AREDS2 is not a multivitamin replacement)
Atlas position: lutein / zeaxanthin is the key to a complete eye-health teaching on the atlas — AREDS2 is a rare nutritional RCT with high-quality long follow-up and hard endpoints, it must be covered. But whole foods first; supplements are valuable only in specific populations.
Q1: What is your situation?
Healthy adult with greens / eggs in diet: food is sufficient, no supplement neededEarly / intermediate AMD: AREDS2 formula (vit C + E + Zn + Cu + lutein 10 + zea 2 mg) — under ophthalmologist guidanceAMD family history + 50+ y/o: consider prophylactic supplementation, discuss with ophthalmologyLong-term sun exposure + blue / light eyes: high AMD risk, sameCataract: no strong evidence, but supplementation acceptable
Q2: Choosing the form:
AREDS2 combination (full formula): major brands (PreserVision AREDS2, etc.) — standardSingle-ingredient lutein/zea: cheaper, but lacks the vit C + E + Zn + Cu synergyNatural source (marigold): dominant lutein source
Q3: Dose:
AREDS2 standard: 10 mg lutein + 2 mg zea/dayHigher doses (20 + 4 mg): some signal but weak evidenceMPOD testing: available at some ophthalmology clinics, assesses individual need
Q4: Take with fat:
Carotenoids must be co-ingested with fat for absorptionTake with a meal containing fatFasting absorption < 5%
Time to effect:
MPOD changes: 2-6 monthsAMD progression slowing: 1-3 years (chronic disease)"Instant sharper vision": wrong expectation — supplements do not immediately improve vision
Safety:
Very safe — food doses are extremely high (yellow skin from carotenes is pigment accumulation, not toxicity)AREDS2 dose: 5-year long-term safety data goodVery high doses (40+ mg/day): rare GI side effects
Don't buy:
"Anti-blue-light eye-care" combinations: overloaded formula + not on-target + marketing premium"Anti-myopia / lower diopter": no supplement reduces myopia (myopia is axial elongation, not pigment)"Children's eye-care gummies": mostly sugar + flavouring, low lutein content, real food is better
Connections to other atlas stories:
vitamin-a/vision L4 (complete visual chemistry)integumentary/uv-photoaging L4 (UV damage)fats-omega-3 + fish-oil (omega-3 was ineffective in AMD, review)multi-vitamin (AREDS2 is not a multivitamin replacement)
Atlas position: lutein / zeaxanthin is the key to a complete eye-health teaching on the atlas — AREDS2 is a rare nutritional RCT with high-quality long follow-up and hard endpoints, it must be covered. But whole foods first; supplements are valuable only in specific populations.
Screen blue light + dry eye debunked
"Long screen-time → macular degeneration / blindness" is the biggest ophthalmology marketing line of the past decade — the atlas must make this clear.Real intensity of screen blue light:
Sunlight: blue light ~ 30 W/m² (clear-day outdoors)Phone screen at 30 cm: blue light ~ 0.05 W/m² (~ 600× lower than sunlight)Computer screen at 50 cm: ~ 0.02 W/m²
Conclusion: screen blue-light dose is far below natural sunlight. The "screens cause AMD" claim is not supported dosimetrically.
Real AMD risk factors:
1. Age (> 65)
2. Genetics (CFH / ARMS2)
3. Smoking (risk ↑ 2-3×)
4. White / Caucasian
5. High long-term UV exposure (outdoor work + high altitude)
6. Poor nutrition (lutein/zeaxanthin / zinc / vit C/E)
7. Cardiovascular disease + hypertension + high BMI
Screens are not in the top 10. Don't let "anti-blue-light glasses" marketing scare you.
"Digital eye strain (DES)" is real, but it is not AMD:
Mechanism: blink rate falls (12-15/min → 3-7) → dry eye; ciliary muscle sustained tension; night-time screens → delayed melatonin (atlas insomnia).
What actually works:
20-20-20 rule: every 20 minutes, look 20 feet (6 m) away for 20 secondsActive blinking + eye lubricant (preservative-free artificial tears)Screen 50-70 cm + sight line slightly downwardAdequate lighting + night-mode blue-shiftDistance viewing + outdoors (strongest evidence for childhood myopia prevention)
Truth about "anti-blue-light glasses":
Cochrane 2023 (17 RCTs, N = 619): no significant evidence of improvement in eye strain + sleep + macular degenerationSubjective benefit in some people = placeboNot harmful, but not worth the premium
Childhood myopia prevention (China 50%+ of high-schoolers):
2 hours/day outdoors = the only intervention with strong evidence (sunlight → retinal dopamine → inhibits axial elongation)It is not "less phone time," it is "more daylight"
Atlas connections: insomnia (night-time blue light delays melatonin) + circadian (light is the suprachiasmatic nucleus: The brain's master clock — set by light, it runs the body's day–night rhythm. input).
选型与剂量 · 买之前对着勾
Lutein/Zeaxanthin 决策路径 (下面的 AMD 都指老年黄斑变性)Q1: 你的情况?
健康成人, 饮食里有绿叶菜和蛋: 食物足够, 不需补剂早期、中期 AMD: AREDS2 公式 (Vit C + E + Zn + Cu + Lutein 10 + Zea 2 mg), 眼科医生指导有 AMD 家族史、又过了 50 岁: 考虑预防性补充, 与眼科协商长期日光暴露, 蓝色眼、浅虹膜: 高 AMD 风险, 同上白内障: 无强证据, 但可补
Q2: 形态选择:
AREDS2 复方 (整套配方): 大品牌 (PreserVision AREDS2 等), 标准单方 Lutein/Zea: 便宜, 但缺少 Vit C + E + Zn + Cu 协同天然来源 (万寿菊 marigold): Lutein 主流来源
Q3: 剂量:
AREDS2 标准: 10 mg Lutein + 2 mg Zea/天更高剂量 (20 + 4 mg): 信号有, 但证据不强MPOD 测试: 部分眼科诊所可测, 用于评估个人需求
Q4: 与脂肪同服:
类胡萝卜素必须与脂同吸收随一顿含脂主餐服用空腹吸收 < 5%
何时见效:
MPOD 改变: 2–6 个月AMD 进展减缓: 1–3 年 (慢性病)视力立刻清晰是错误期待, 补剂不会立刻改善视力
安全性:
极安全: 食物剂量可以很大 (胡萝卜素让皮肤变黄是色素积累, 不是中毒)AREDS2 剂量: 长期 5 年安全数据好超大剂量 (40+ mg/天): 极少数人有胃肠不适
不该买:
抗蓝光眼睛保养复合: 配方过载、不对症、营销溢价抗近视、降度数: 没有任何补剂能降近视度数 (近视是眼轴变长, 不是色素问题)儿童护眼软糖: 大部分是糖和香精, Lutein 量少, 不如真食物
与其它故事的闭环:
vitamin-a/vision L4 (视觉化学完整背景)integumentary/uv-photoaging L4 (UV 损伤)fats-omega-3 与 fish-oil (omega-3 在 AMD 无效, 可复习)multi-vitamin (AREDS2 不是 multivitamin 替代)
叶黄素、玉米黄质是眼健康这块拼图的关键——AREDS2 是营养学罕见的高质量长随访硬终点 RCT, 不能不讲。但整食物优先, 补剂只在特定人群中价值才大。
机制 · 三件事同出一条链
决策树上那些条目看着零散, 其实全是同一条链的推论。把链摆出来, 你不用记表格。为什么必须和脂肪一起吃? 叶黄素是脂溶的。在肠道里, 它得先溶进油滴, 再被包进一颗乳糜微粒这样的运输小球, 才有资格离开肠道进入淋巴、汇进血液。空腹时肠道里没有油滴, 也就没有车; 分子原样过境, 从粪便里出去。这一步不是效率高低的问题, 是有和没有的问题。
为什么要几个月才看得到色素密度变化? 因为进了血还只走完第一段。黄斑要把它们从血里挑出来、拽进去、插进膜里固定住, 而每天能搬进去的量是有限的。色素层的厚度是一点点堆出来的, 像往墙上刷漆: 一遍看不出来, 遍数攒够才看得出颜色。
为什么再往上加剂量收益就不明显了? 因为限速的那一步不在嘴里, 在那道门。血里浓度再高, 黄斑每天能接收的量有上限; 超出去的部分只是在血里转一圈, 或者堆进皮肤——这就是吃太多胡萝卜素皮肤会发黄的原因, 那是色素积在角质层, 不是中毒。吃得更多, 不等于黄斑收得更多。
为什么效果只能是进展变慢? 因为这层色素干的是预防性的活: 挡住还没打进来的光, 替还没被氧化的膜先挨一下。它对已经发生的损伤没有任何手段。所以合理的期待是以后坏得慢一点, 不是现在看得清一点。任何承诺立刻变清楚的护眼产品, 承诺的都是这条链做不到的事。
为什么医生非要看眼底才肯下结论? 因为这条链的中段——RPE 底下有没有开始堆东西、堆了多少——只能看见, 不能感觉。等你自己察觉到中央视野不对, 链条已经走到很后面了。眼底检查看的是这条链的现在进行时, 而症状报告的是它的完成时。 这就是为什么这一幕反复把决定权交回给眼科医生: 不是免责, 是因为你手上缺的正是那张眼底照片。
References · 5
- Age-Related Eye Disease Study 2 Research Group. (2013). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA, 309(19), 2005-2015. 10.1001/jama.2013.4997
- Chung, H. Y., Rasmussen, H. M., & Johnson, E. J. (2004). Lutein bioavailability is higher from lutein-enriched eggs than from supplements and spinach in men. The Journal of Nutrition, 134(8), 1887-1893. Egg lutein, packaged with fat, is absorbed more efficiently than from spinach. 10.1093/jn/134.8.1887
- Hammond, B. R., Miller, L. S., Bello, M. O., Lindbergh, C. A., Mewborn, C., Renzi-Hammond, L. M. (2017). Effects of Lutein/Zeaxanthin Supplementation on the Cognitive Function of Community Dwelling Older Adults: A Randomized, Double-Masked, Placebo-Controlled Trial. Frontiers in Aging Neuroscience, 9. The real Hammond 2017: lutein/zeaxanthin supplementation and visual/cognitive function in healthy adults. It is not CARMA — CARMA is Beatty/Chakravarthy, enrolled people WITH age-related macular degeneration, had no omega-3 arm, and reported in 2013. 10.3389/fnagi.2017.00254
- Bone, R. A., Landrum, J. T., Cao, Y., Howard, A. N., Alvarez-Calderon, F. (2007). Macular pigment response to a supplement containing meso-zeaxanthin, lutein and zeaxanthin. Nutrition & Metabolism, 4(1), 12. 120 days, 10 supplemented plus 9 placebo, 20 mg/day of a MESO-ZEAXANTHIN-dominant supplement. Its only outcome is the rate of rise of macular pigment optical density — it measured no reading speed and no visual processing. 10.1186/1743-7075-4-12
- Singh, S., Keller, P. R., Busija, L., McMillan, P., Makrai, E., Lawrenson, J. G., Hull, C. C., & Downie, L. E. (2023). Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults. Cochrane Database of Systematic Reviews, (8), CD013244. No clear short-term advantage for reducing eye strain from computer use; unclear effects on sleep and vision; no evidence of retinal protection. 10.1002/14651858.CD013244.pub2